Aberdeen Group
NVCR icon

Aberdeen Group’s NovoCure NVCR Stock Holding History

Aberdeen Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-36,339
Closed -$587K – 974
2023
Q3 		$587K Sell
36,339
-9,088
-20% -$262K ﹤0.01% 802
2023
Q2 		$1.89M Buy
45,427
+1,672
+4% +$104K ﹤0.01% 730
2023
Q1 		$2.63M Buy
43,755
+10,746
+33% +$859K 0.01% 694
2022
Q4 		$2.42M Buy
33,009
+1,290
+4% +$97.1K 0.01% 681
2022
Q3 		$2.41M Buy
31,719
+10,474
+49% +$817K 0.01% 676
2022
Q2 		$1.48M Buy
21,245
+2,325
+12% +$175K ﹤0.01% 745
2022
Q1 		$1.56M Buy
18,920
+3,595
+23% +$265K ﹤0.01% 765
2021
Q4 		$1.15M Buy
15,325
+859
+6% +$86.2K ﹤0.01% 854
2021
Q3 		$1.68M Buy
14,466
+3,035
+27% +$459K ﹤0.01% 814
2021
Q2 		$2.54M Sell
11,431
-2,286
-17% -$445K 0.01% 727
2021
Q1 		$1.81M Buy
13,717
+8,072
+143% +$1.28M ﹤0.01% 777
2020
Q4 		$978K Buy
5,645
+1,230
+28% +$168K ﹤0.01% 833
2020
Q3 		$492K Buy
+4,415
New +$353K ﹤0.01% 850

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Aberdeen Group's NVCR Position: Q4 2023 in Review

Aberdeen Group sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 36,339 shares — an estimated $587K sold.

Aberdeen Group first reported a position in NVCR in Q3 2020 and held it in 13 quarters. The position peaked at $2.63M in Q1 2023. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • Aberdeen Group reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • Aberdeen Group sold 36,339 NovoCure shares in Q4 2023, an estimated $587K.
  • Aberdeen Group first reported a position in NovoCure in Q3 2020 and held it in 13 quarters.
  • Aberdeen Group's NovoCure position peaked at $2.63M in Q1 2023.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Aberdeen Group's 13F filing for Q4 2023, filed 31 Jan 2024.